EP2224924A4 - Compositions and methods for treating cystic fibrosis - Google Patents

Compositions and methods for treating cystic fibrosis

Info

Publication number: EP2224924A4
Authority: EP; European Patent Office
Prior art keywords: compositions; methods; cystic fibrosis; treating cystic; treating
Prior art date: 2007-10-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP08841991A

Other languages

German (de)

French (fr)

Other versions

EP2224924A1 (en

Inventor

Richard L Watson

Anthony B Wood

Gregory J Archambeau

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Microdiffusion Inc

Original Assignee

Microdiffusion Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-25

Filing date

2008-10-24

Publication date

2011-01-12

2007-10-25 Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/en

2007-10-25 Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/en

2007-10-25 Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/en

2008-10-24 Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc

2008-10-24 Priority claimed from PCT/US2008/081113 external-priority patent/WO2009055671A1/en

2010-09-08 Publication of EP2224924A1 publication Critical patent/EP2224924A1/en

2011-01-12 Publication of EP2224924A4 publication Critical patent/EP2224924A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Zoology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)

EP08841991A 2007-10-25 2008-10-24 Compositions and methods for treating cystic fibrosis Withdrawn EP2224924A4 (en)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date	Title
US98272007P	2007-10-25	2007-10-25
US98271907P	2007-10-25	2007-10-25
PCT/US2007/082580 WO2008052145A2 (en)	2006-10-25	2007-10-25	Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
PCT/US2007/082581 WO2008115290A2 (en)	2006-10-25	2007-10-25	Methods of wound care and treatment
PCT/US2007/082578 WO2008052143A2 (en)	2006-10-25	2007-10-25	Mixing device and output fluids of same
US4834008P	2008-04-28	2008-04-28
US4833208P	2008-04-28	2008-04-28
US4834708P	2008-04-28	2008-04-28
US4840408P	2008-04-28	2008-04-28
PCT/US2008/081113 WO2009055671A1 (en)	2007-10-25	2008-10-24	Compositions and methods for treating cystic fibrosis

Publications (2)

Publication Number	Publication Date
EP2224924A1 EP2224924A1 (en)	2010-09-08
EP2224924A4 true EP2224924A4 (en)	2011-01-12

Family

ID=42261767

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP08842968A Withdrawn EP2215260A4 (en)	2007-10-25	2008-10-23	Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
EP08841991A Withdrawn EP2224924A4 (en)	2007-10-25	2008-10-24	Compositions and methods for treating cystic fibrosis
EP08841701.9A Active EP2214707B1 (en)	2007-10-25	2008-10-24	Compositions and methods for treating inflammation

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP08842968A Withdrawn EP2215260A4 (en)	2007-10-25	2008-10-23	Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP08841701.9A Active EP2214707B1 (en)	2007-10-25	2008-10-24	Compositions and methods for treating inflammation

Country Status (8)

Country	Link
EP (3)	EP2215260A4 (en)
JP (6)	JP5613565B2 (en)
CN (5)	CN101910412B (en)
AU (3)	AU2008316794B2 (en)
CA (3)	CA2703672A1 (en)
IL (3)	IL205318A (en)
MX (3)	MX2010004563A (en)
WO (1)	WO2009055614A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6702949B2 (en)	1997-10-24	2004-03-09	Microdiffusion, Inc.	Diffuser/emulsifier for aquaculture applications
WO2008052143A2 (en)	2006-10-25	2008-05-02	Revalesio Corporation	Mixing device and output fluids of same
US8597689B2 (en)	2006-10-25	2013-12-03	Revalesio Corporation	Methods of wound care and treatment
US8445546B2 (en)	2006-10-25	2013-05-21	Revalesio Corporation	Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US9745567B2 (en)	2008-04-28	2017-08-29	Revalesio Corporation	Compositions and methods for treating multiple sclerosis
US10125359B2 (en)	2007-10-25	2018-11-13	Revalesio Corporation	Compositions and methods for treating inflammation
MX2010004549A (en) *	2007-10-25	2010-07-28	Revalesio Corp	Bacteriostatic or bacteriocidal compositions and methods.
US9523090B2 (en)	2007-10-25	2016-12-20	Revalesio Corporation	Compositions and methods for treating inflammation
CA2703672A1 (en) *	2007-10-25	2009-04-30	Revalesio Corporation	Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
JP5539965B2 (en) *	2008-04-28	2014-07-02	レバレジオコーポレイション	Compositions and methods for treating multiple sclerosis
MX2010011856A (en)	2008-05-01	2011-02-15	Revalesio Corp	Compositions and methods for treating digestive disorders.
MX337035B (en) *	2008-10-22	2016-02-09	Revalesio Corp	Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions.
CN102413817B (en) *	2009-04-27	2014-12-17	利发利希奥公司	Compositions and methods for treating insulin resistance and diabetes mellitus
US8815292B2 (en)	2009-04-27	2014-08-26	Revalesio Corporation	Compositions and methods for treating insulin resistance and diabetes mellitus
MX2012012971A (en)	2010-05-07	2013-02-07	Revalesio Corp	Compositions and methods for enhancing physiological performance and recovery time.
EP2799071B1 (en)	2010-06-16	2018-10-17	Inflammatory Response Research, Inc.	Levocetirizine and montelukast for the treatment of influenza and common cold
CN103347500A (en)	2010-08-12	2013-10-09	利发利希奥公司	Compositions and methods for treatment of taupathy
CA2808192A1 (en) *	2010-08-13	2012-02-16	Revalesio Corporation	Compositions and methods for treating cardiovascular disease
MX2013011888A (en) *	2011-04-13	2014-02-27	Revalesio Corp	Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease.
JP6368459B2 (en) *	2012-06-14	2018-08-01	松本　高明	Method for producing ophthalmic solution
KR20160125283A (en)	2013-03-13	2016-10-31	인플래머토리 리스폰스 리서치, 아이엔씨.	Use of levocetirizine and montelukast in the treatment of autoimmune vasculitis
JP6441888B2 (en)	2013-03-13	2018-12-19	インフラマトリー・レスポンス・リサーチ・インコーポレイテッド	Use of levocetirizine and montelukast in the treatment of autoimmune disorders
RU2672871C2 (en)	2013-03-13	2018-11-20	Инфламматори Респонс Ресёрч, Инк.	Use of levocetirizine and montelukast in treatment of traumatic injury
EP3193875B1 (en)	2014-09-15	2022-02-16	Inflammatory Response Research, Inc.	Levocetirizine and montelukast in the treatment of inflammation mediated conditions
CN106943593A (en) *	2017-03-24	2017-07-14	浙江中医药大学	Application of the anti-TSLP antibody in the chronic itch medicine of preventing and treating is prepared
WO2018213882A1 (en) *	2017-05-23	2018-11-29	Biovite Australia Pty Ltd	Extracts from arthrospira and uses thereof
CN112305153B (en) *	2020-10-16	2022-09-23	中石化石油工程技术服务有限公司	Automatic analysis detector for bentonite content and detection method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040129112A1 (en) *	2000-07-27	2004-07-08	Gillis Scott H.	Metal-containing materials
WO2005113026A2 (en) *	2004-04-22	2005-12-01	Medical Discoveries, Inc.	Method of treating respiratory disorders and airway inflammation
WO2008052143A2 (en) *	2006-10-25	2008-05-02	Revalesio Corporation	Mixing device and output fluids of same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9518483D0 (en) *	1995-09-09	1995-11-08	Thompson Royce Ltd	Lighting control systems
US7654728B2 (en) *	1997-10-24	2010-02-02	Revalesio Corporation	System and method for therapeutic application of dissolved oxygen
US6386751B1 (en) *	1997-10-24	2002-05-14	Diffusion Dynamics, Inc.	Diffuser/emulsifier
CN1178952C (en) *	1998-07-28	2004-12-08	加利福尼亚大学董事会	Nucleic acid encoding a G-protein coupled receptor involved in sensory transduction
US20060198901A9 (en) *	1999-10-26	2006-09-07	Holloway William D Jr	Drugs, bio-affecting and body treating compositions
NZ518605A (en) *	1999-10-26	2004-03-26	Bio Hydration Res Lab Inc	Micro-cluster liquids and methods of making and using them
WO2001042451A2 (en) *	1999-12-08	2001-06-14	Genset	FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
WO2002024222A2 (en) *	2000-09-20	2002-03-28	The Cleveland Clinic Foundation	Ligands for g protein coupled receptors and methods of using them
US20040235732A1 (en) *	2000-11-03	2004-11-25	Qun-Yong Zhou	Method for modulating angiogenesis using prokineticin receptor antagonists
EP1357920B1 (en) *	2001-02-01	2007-09-05	Hydron Technologies Inc.	Compositions and method of tissue superoxygenation
GB0118383D0 (en) *	2001-07-27	2001-09-19	Pharmagene Lab Ltd	Therapeutic methods
DE10227818A1 (en) *	2002-06-21	2004-01-08	Pakdaman, Abolghassem, Prof. Dr.med.	Gas enrichment modules
AU2002321678A1 (en) *	2002-09-09	2004-03-29	Boros Béla	Oxygen-enriched water, treated within a magnetic field and heavy water
US7790762B2 (en) *	2002-10-31	2010-09-07	National Jewish Health	Compounds and methods for thiol-containing compound efflux and cancer treatment
US7491695B2 (en) *	2003-06-18	2009-02-17	Tranzyme Pharma Inc.	Methods of using macrocyclic modulators of the ghrelin receptor
ATE500234T1 (en) *	2003-11-10	2011-03-15	Merck Sharp & Dohme	SUBSTITUTED TRIALZOLES AS A SODIUM CHANNEL BLOCKER
US20050139808A1 (en) *	2003-12-30	2005-06-30	Oculus Innovative Sciences, Inc.	Oxidative reductive potential water solution and process for producing same
DE602005014393D1 (en) *	2005-03-28	2009-06-18	Dabur Pharma Ltd	STABLE PHARMACEUTICAL COMPOSITIONS OF ANTITUMOROUS PLATINUM (II) AGENTS
WO2006125132A2 (en) *	2005-05-18	2006-11-23	Mpex Pharmaceuticals, Inc.	Aerosolized fluoroquinolones and uses thereof
GB0603683D0 (en) *	2006-02-23	2006-04-05	Novartis Ag	Organic compounds
WO2008115290A2 (en) *	2006-10-25	2008-09-25	Revalesio Corporation	Methods of wound care and treatment
US8597689B2 (en) *	2006-10-25	2013-12-03	Revalesio Corporation	Methods of wound care and treatment
CA2703672A1 (en) *	2007-10-25	2009-04-30	Revalesio Corporation	Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
MX2010004549A (en) *	2007-10-25	2010-07-28	Revalesio Corp	Bacteriostatic or bacteriocidal compositions and methods.

2008
- 2008-10-23 CA CA2703672A patent/CA2703672A1/en not_active Abandoned
- 2008-10-23 JP JP2010531255A patent/JP5613565B2/en not_active Expired - Fee Related
- 2008-10-23 MX MX2010004563A patent/MX2010004563A/en active IP Right Grant
- 2008-10-23 CN CN200880122893XA patent/CN101910412B/en not_active Expired - Fee Related
- 2008-10-23 AU AU2008316794A patent/AU2008316794B2/en not_active Ceased
- 2008-10-23 WO PCT/US2008/081021 patent/WO2009055614A1/en active Application Filing
- 2008-10-23 EP EP08842968A patent/EP2215260A4/en not_active Withdrawn
- 2008-10-24 CN CN201410108422.0A patent/CN103933567A/en active Pending
- 2008-10-24 CN CN201510111837.8A patent/CN104771758A/en active Pending
- 2008-10-24 CN CN200880122816.4A patent/CN101909623B/en not_active Expired - Fee Related
- 2008-10-24 EP EP08841991A patent/EP2224924A4/en not_active Withdrawn
- 2008-10-24 AU AU2008316623A patent/AU2008316623B2/en active Active
- 2008-10-24 AU AU2008316663A patent/AU2008316663B2/en not_active Ceased
- 2008-10-24 JP JP2010531276A patent/JP5911197B2/en not_active Expired - Fee Related
- 2008-10-24 CA CA2703754A patent/CA2703754C/en active Active
- 2008-10-24 CN CN200880122817.9A patent/CN101909648B/en active Active
- 2008-10-24 JP JP2010531290A patent/JP5869763B2/en active Active
- 2008-10-24 MX MX2010004564A patent/MX2010004564A/en active IP Right Grant
- 2008-10-24 MX MX2010004554A patent/MX2010004554A/en active IP Right Grant
- 2008-10-24 CA CA2703739A patent/CA2703739A1/en not_active Abandoned
- 2008-10-24 EP EP08841701.9A patent/EP2214707B1/en active Active
2010
- 2010-04-25 IL IL205318A patent/IL205318A/en active IP Right Grant
- 2010-04-25 IL IL205319A patent/IL205319A/en not_active IP Right Cessation
- 2010-04-25 IL IL205317A patent/IL205317A/en not_active IP Right Cessation
2014
- 2014-06-06 JP JP2014117564A patent/JP2014193915A/en active Pending
- 2014-06-12 JP JP2014121357A patent/JP2014205693A/en not_active Withdrawn
- 2014-06-12 JP JP2014121350A patent/JP2014169328A/en not_active Withdrawn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040129112A1 (en) *	2000-07-27	2004-07-08	Gillis Scott H.	Metal-containing materials
WO2005113026A2 (en) *	2004-04-22	2005-12-01	Medical Discoveries, Inc.	Method of treating respiratory disorders and airway inflammation
WO2008052143A2 (en) *	2006-10-25	2008-05-02	Revalesio Corporation	Mixing device and output fluids of same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILL S ET AL: "Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - A review", JOURNAL OF BIOMEDICAL NANOTECHNOLOGY 200706 US LNKD- DOI:10.1166/JBN.2007.015, vol. 3, no. 2, June 2007 (2007-06-01), pages 107 - 119, XP009141494, ISSN: 1550-7033 *
See also references of WO2009055671A1 *

Also Published As

Publication number	Publication date
AU2008316623A1 (en)	2009-04-30
IL205318A0 (en)	2010-12-30
JP2011500844A (en)	2011-01-06
CA2703739A1 (en)	2009-04-30
CN101910412B (en)	2013-08-21
JP5613565B2 (en)	2014-10-22
AU2008316794A1 (en)	2009-04-30
EP2214707A1 (en)	2010-08-11
WO2009055614A1 (en)	2009-04-30
IL205317A0 (en)	2010-12-30
CN101910412A (en)	2010-12-08
EP2214707A4 (en)	2011-04-20
JP5869763B2 (en)	2016-02-24
JP2011500847A (en)	2011-01-06
CA2703672A1 (en)	2009-04-30
MX2010004564A (en)	2010-07-28
CA2703754A1 (en)	2009-04-30
AU2008316663B2 (en)	2014-12-18
IL205319A (en)	2016-06-30
EP2214707B1 (en)	2017-07-12
JP2014169328A (en)	2014-09-18
CN101909648A (en)	2010-12-08
CN101909623B (en)	2015-04-01
CN101909648B (en)	2014-04-16
EP2224924A1 (en)	2010-09-08
AU2008316794B2 (en)	2015-04-23
CA2703754C (en)	2019-04-09
JP5911197B2 (en)	2016-04-27
MX2010004563A (en)	2010-07-28
EP2215260A4 (en)	2011-04-20
MX2010004554A (en)	2010-07-28
JP2014193915A (en)	2014-10-09
AU2008316663A1 (en)	2009-04-30
JP2014205693A (en)	2014-10-30
CN101909623A (en)	2010-12-08
JP2011500837A (en)	2011-01-06
IL205319A0 (en)	2010-12-30
CN104771758A (en)	2015-07-15
IL205317A (en)	2016-03-31
CN103933567A (en)	2014-07-23
EP2215260A1 (en)	2010-08-11
IL205318A (en)	2017-01-31
AU2008316623B2 (en)	2015-01-22

Publication	Publication Date	Title
EP2224924A4 (en)	2011-01-12	Compositions and methods for treating cystic fibrosis
HRP20190214T1 (en)	2019-03-22	Compositions and methods for treating purpura
EP2170309A4 (en)	2010-11-03	Methods and compositions for treating disorders
EP2120561A4 (en)	2012-11-21	Compositions for treating biofilms and methods for using same
ZA201001300B (en)	2010-11-24	Antigen-asjuvant compositions and methods
IL186599A0 (en)	2008-01-20	Methods for treating and preventing fibrosis
GB2466912B (en)	2012-01-04	Compositions and methods for treating lysosomal disorders
IL185540A0 (en)	2008-08-07	Compositions and methods for treating acne
IL202184A0 (en)	2011-08-01	Methods and compositions for increased transgene expression
EP1986952A4 (en)	2011-03-30	Methods of treating cystic fibrosis
EP1981491A4 (en)	2009-09-23	Formulations and methods for treating dry eye
HK1165293A1 (en)	2012-10-05	Composition for the treatment of cystic fibrosis
ZA200900140B (en)	2009-12-30	Methods and compositions for treating biofilms
IL210097A0 (en)	2011-02-28	Compositions and methods for treating unfluenza
GB0906630D0 (en)	2009-06-03	Compositions and method for hair loss prevention
GB0709781D0 (en)	2007-06-27	Composition and method
GB0721291D0 (en)	2007-12-12	Methods and compositions
HUP0700369D0 (en)	2007-07-30	Pharmaceutical compositions and method for treating schizofrenia
SI2007895T1 (en)	2015-04-30	Compositions and methods for therapy of cystic fibrosis
GB0619500D0 (en)	2006-11-08	Treatment of fibrosis
EP2182943A4 (en)	2010-10-06	Methods and compositions for treating fibrosis related disorders using il-17 antagonists
EP2205271A4 (en)	2012-07-11	Compositions and methods for ribonuclease-based therapies
GB0719526D0 (en)	2007-11-14	Compositions and methods
EP2094279A4 (en)	2010-12-29	Methods and compositions for treating influenza
GB0714500D0 (en)	2007-09-05	composition and treatment

Legal Events

Date	Code	Title	Description
2010-08-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2010-09-08	17P	Request for examination filed	Effective date: 20100521
2010-09-08	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2010-09-08	AX	Request for extension of the european patent	Extension state: AL BA MK RS
2011-01-12	A4	Supplementary search report drawn up and despatched	Effective date: 20101213
2011-02-02	DAX	Request for extension of the european patent (deleted)
2014-09-24	17Q	First examination report despatched	Effective date: 20140822
2016-09-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2016-11-02	18W	Application withdrawn	Effective date: 20160927